A detailed history of Black Rock Inc. transactions in Beyond Spring Inc. stock. As of the latest transaction made, Black Rock Inc. holds 215,355 shares of BYSI stock, worth $398,406. This represents 0.0% of its overall portfolio holdings.

Number of Shares
215,355
Previous 215,163 0.09%
Holding current value
$398,406
Previous $768,000 32.81%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$1.76 - $3.6 $337 - $691
192 Added 0.09%
215,355 $516,000
Q1 2024

May 10, 2024

SELL
$0.85 - $3.63 $7,753 - $33,112
-9,122 Reduced 4.07%
215,163 $768,000
Q4 2023

Feb 13, 2024

SELL
$0.67 - $1.12 $7,733 - $12,927
-11,542 Reduced 4.89%
224,285 $201,000
Q3 2023

Nov 13, 2023

SELL
$0.75 - $1.16 $5,580 - $8,631
-7,441 Reduced 3.06%
235,827 $188,000
Q2 2023

Aug 11, 2023

BUY
$0.89 - $1.39 $4,498 - $7,026
5,055 Added 2.12%
243,268 $287,000
Q1 2023

May 12, 2023

SELL
$1.06 - $3.05 $64,371 - $185,220
-60,728 Reduced 20.31%
238,213 $266,000
Q4 2022

Feb 13, 2023

SELL
$0.56 - $2.61 $17,893 - $83,394
-31,952 Reduced 9.66%
298,941 $562,000
Q3 2022

Nov 14, 2022

SELL
$0.97 - $1.81 $22,472 - $41,934
-23,168 Reduced 6.54%
330,893 $327,000
Q2 2022

Aug 12, 2022

SELL
$1.13 - $2.66 $1.7 Million - $4.01 Million
-1,507,158 Reduced 80.98%
354,061 $509,000
Q1 2022

May 12, 2022

BUY
$1.68 - $5.01 $538,319 - $1.61 Million
320,428 Added 20.8%
1,861,219 $4.1 Million
Q4 2021

Feb 10, 2022

SELL
$4.02 - $16.84 $245,943 - $1.03 Million
-61,180 Reduced 3.82%
1,540,791 $6.98 Million
Q3 2021

Nov 09, 2021

BUY
$9.26 - $31.31 $1.7 Million - $5.75 Million
183,801 Added 12.96%
1,601,971 $25.2 Million
Q2 2021

Aug 11, 2021

BUY
$9.37 - $12.12 $13.3 Million - $17.2 Million
1,418,170 New
1,418,170 $14.8 Million

Others Institutions Holding BYSI

About BeyondSpring Inc.


  • Ticker BYSI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,928,900
  • Market Cap $72M
  • Description
  • BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and...
More about BYSI
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.